EMA Hosts Antimicrobial Resistance Meeting
The meeting, to be held jointly with the European Centre for Disease Prevention and Control, is part of the agency’s effort to raise awareness about the threat of antimicrobial resistance.
On Sept. 12, 2017, the European Medicines Agency (EMA) announced a joint meeting with the European Centre for Disease Prevention and Control (ECDC), to be held on Sept. 19, 2017 in London, to discuss the threat of antimicrobial resistance. The meeting will be attended by representatives of the World Health Organization, the European Commission, European Union Member States, patients’ and consumers’ organizations, healthcare professionals, and academics.
The purpose of the meeting is to raise awareness of the threat of antimicrobial resistance and to understand how EMA and ECDC can support European healthcare initiatives against the threat. According to EMA, the threat is rising, with a growing number of infections becoming increasingly resistant to antibiotics. This resistance makes treatment difficult, and EMA and other agencies feel the fight requires a global collaboration.
The draft agenda for the meeting includes overviews of EMA’s and ECDC’s efforts and how other organizations can join in with those efforts. The meeting will be broadcast live on EMA’s website, and a report will be published after the event.
Source: EMA
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
